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MiR-200a hasbeen reported tobeable to suppress the epithelial-mesenchymal transitionprocess inpancreatic cancer
stem cells, suggesting that miR-200a could suppress the metastasis of pancreatic ductal adenocarcinoma (PDAC).
However, its role in proliferation and metastasis of PDAC and the underlying mechanism by which miR-200a works in
PDAC have not been elucidated. In our study, we for the first time identified that DEK gene is a direct downstream
target of miR-200a. It was found that overexpression of miR-200a decreased DEK expression, suppressing the
proliferation, migration, and invasion of PDAC cells. Meanwhile, knockdown of miR-200a can increase DEK level,
promoting the proliferation,migration, and invasion of PDACcells. Our study demonstrated thatmiR-200a suppresses
themetastasis in pancreatic PDAC through downregulation of DEK, suggesting thatmiR-200amay be used as a novel
potential marker in prediction of metastasis of PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with the
lowest prognosis, with the majority of patients diagnosed with advanced
disease that often happened to metastasize from lymph nodes to distant
organs [1]. Therefore, there is a great need to understand the biological
mechanisms that contribute to pancreatic cancer development and
progression so as to develop effective therapies.
MiR-200a has been reported to be able to suppress the epithelial-mesench-
ymal transition process, which is a critical step for the initiation of cancer
metastasis, ofpancreatic cancer stemcell [2] andcolorectal carcinomacell [3]. In
addition, miR-200a has also been found to suppress cell proliferation and
migration in pancreatic cancer [4] and hepatocellular carcinoma [5]. Based on
the four relevant literatures, it can be hypothesized that miR-200a could
suppress the proliferation and metastasis of PDAC. However, the role of
miR-200a in PDACand the underlyingmechanismhave not been elucidated.
DEK protein was originally related to chromatin reconstruction [6]
and transcription factor involved in stabilization of heterochromatin
and cruciform structures [7]. Subsequently, it has been increasingly
found to be generally overexpressed in various cancers, being shown to
play an important role in the development and progression of different
types of cancers [7,8]. In pancreatic cancer, DEK gene was first
mentioned and found to be upregulated among the most significantlydifferential genes that related to liver metastasis [9], indicating its role as
a metastasis associated gene in PDAC. Besides, there has been, however,
no more subsequent study to follow the role of DEK in PDAC.
In the present study, we for the first time identified and found that
DEK gene is a direct downstream target of miR-200a. Our study
demonstrated that miR-200a suppresses both the proliferation and
metastasis in PDAC through downregulation of DEK, suggesting that
miR-200a may be used as a novel potential marker in prediction of
metastasis of PDAC.
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Clinical Tissues
The present study was approved by the Medical Ethics Committee
of the First Affiliated Hospital of Xinjiang Medical University. Tissue
microarray used for immunostaining analysis of DEK was purchased
from Shanghai Outdo Biotech. Co. Ltd. (Shanghai, China). The
array consisted of 81 cases of pancreatic cancer and 79 cases of paired
adjacent normal control. Staging and grading were assessed in
accordance with the World Health Organization classification and
grading system. None of the patients received chemoradiotherapy
before operation. Informed consents were obtained for all the subjects
involved, as proclaimed by the company. Eighty-one cases of fresh
pancreatic cancer tissues and paired normal control were collected in
the Department of Pathology, which was reserved in liquid nitrogen
until use.
Cell Lines
Pancreatic cancer cell lines PK-1, KLM-1, PK-8, and AsPC-1 were
purchased from ATCC and maintained following ATCC guidelines.
All the HCC cells were cultured in 5% CO2 at 37°C in RPMI1640
(life Technologies, Inc.) supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Life Technologies, Inc.), 2 mM
L-glutamine, 100 U/ml of penicillin G, and 100 mg/ml of
streptomycin (Life Technologies, Inc.).
siRNA and Quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR)
SiRNA of miR-200a mimics, sense: UAAUACUGCCGGGU
AAUGAUGGA; antisense: CAUCAUUACCCGGCAGUAUUAUU;
miR-200a inhibitor UCCAUCAUUACCCGGCAGUAUUA;
miR-200a scramble sense: GUGGCGAUAGACAAUCGAUGUAU;
antisense: ACAUCGAUUGUCUAUCGCCACUU, which was de-
signed and synthesized by GenePharm Company (GenePharm,
Shanghai, China). Total RNA was extracted using the TRIzol reagent
(Invitrogen). The primers for miR-200a and U6 detection assays were
purchased from Shangong (Shangong, Shanghai, China). Total RNAs
were reverse-transcribed using a specific stem-loop RT primer (50
nmol/l) and theKit (Thermo,USA). TheRT conditions consisted of 15
minutes at 42°C followed by 5 minutes at 98°C. Levels of mature
miRNAs were quantified by qRT-PCR using the SYBR Green
Real-time PCR Master Mix (Thermo, USA). The normalized
expression of each sample was designated as CT and obtained by
dividing the CT value of miR-200a by the U6 CT of the same sample.
The relative amount of miRNA in each sample was calculated using
the comparative CT method. The results are presented as fold change
of expression.
Luciferase Reporter Assay
The psiCHECK-2 dual luciferase vector (Promega Corporation,
Madison, WI) was used to construct the plasmid containing the
3-untranslated region (3-UTR) of DEK. The fragments containing
the predicted wild and mutant sites were directly synthesized
(Genewiz, Inc., Suzhou, China) and then subcloned into the
psiCHECK-2 vector following digestion with XhoI and NotI
restriction enzymes (Thermo Fisher Scientific, Inc., Pittsburgh, PA)
to generate the DEK-3′-UTR-wild and DEK-3-UTR-mutant
vectors. Subsequently, PK-1 cells (1 × 105/well) were seeded into a
24-well plate and co-transfected with 50 ng/well DEK-3-UTR-wildor DEK-3-3′-UTR-mutant vector and 50 nM/well miR-200a mimics
or scrambled microRNA negative control. Following culture for 48
hours, the PK-1 cells were collected, and the luciferase activities were
measured by the Dual-Luciferase Reporter Assay kit (Promega
Corporation) on aTD20/20Luminometer (TurnerDesigns,Westport,
MA). Each experiment was performed in triplicate. The results were
expressed as relative Renilla luciferase activities, which were obtained
following normalization to firefly luciferase activities. All the transient
transfections were performed using Lipofectamine 2000 (Invitrogen
Life Technologies, Carlsbad, CA).
Western Blot Analysis
The cells were lysed after various treatments through RIPA lysis
buffer (Bioteke, Beijing) containing 10 mM PMSF for 30 minutes on
ice, followed by centrifuge at 12,000× g for 10 minutes. The protein
concentration was determined using the Bradford method. Samples
of 40 μg of total protein were subjected to 10% sodium dodecy
sulfate polyacrylamide gel electrophoresis and transferred onto
PVDF membrane (Millipore). The membranes were incubated
with primary antibody against human DEK (dilution at 1:2000,
ab166624, Abcam) for overnight at 4°C followed by horseradish
peroxidase–conjugated secondary antibodies, the immunoblots were
visualized with chemiluminescence with SuperSignal West Femto
Chemiluminescent Substrate (Thermo Scientific, USA), and images
were captured with a Bio-Rad camera system (Bio-Rad, USA).
GAPDH and β-actin were used as the internal loading control. Each
immunoblot was repeated at least three times, and representative
figures were presented.
Cell Proliferation Assay
Cell viability was examined by the methylthiazolyl blue tetrazolium
(MTT) assay (Shangon, Shanghai, China) according to the standard
protocol after transfection with miR-200a mimics or miR-200a
inhibitor for 0, 24, 48, 72, and 96 hours. AsPC-1 and PK-1 cells were
plated in 96-well plates at a density of 5 × 103 cells per well. After
transfection, cell proliferation was assessed. Cells were incubated for 4
hours in 20 μl of MTT at 37°C. The color was developed by
incubating the cells in 150 μl of dimethyl sulfoxide; the absorbance
was detected at 490-nm wave length. The data were obtained from
three independent experiments.
Migration and Invasion Assays In Vitro
Cell migration ability was calculated by the wound healing assay.
AsPC-1 and PK-1 cells were plated in 6-well plate at a concentration
of 4 × 105 cells per well and allowed to form a confluent monolayer
for 24 hours. After the transfection, the monolayer was scratched with
a sterile 10-μl pipette tip, washed with serum free medium to remove
floated and detached cells, and photographed (time 0 and 48 hours)
by inversion fluorescence microscope (Olympus, Japan). Cell culture
inserts (24-well, pore size 8 μm; BD Biosciences) were seeded with
5 × 103 cells in 100 μl of medium with 0.1% FBS. Inserts precoated
with Matrigel (40 μl, 1 mg/ml; BD Biosciences) were used for
invasion assays. Medium with 10% FBS (400 μl) was added to the
lower chamber and served as a chemotactic agent. Noninvasive cells
were wiped from the upper side of the membrane, and cells on the
lower side were fixed in cold methanol (−20°C) and air dried.
PBS and 10% FBS were served as negative and positive control,
respectively. Cell were stained with 0.1% crystal violet (dissolved
in methanol) and counted using the inverted microscope. Each
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were counted per insert.
Immunohistochemistry
Paraffin-embedded liver were sectioned to 4-μm thickness.
Peroxidase blockage and visualization were achieved with Dako
Envision+ system (Dako, Denmark). Following heat-induced epitope
retrieval according to manufacturer’s protocol, incubation with
monoclonal antibodies against human DEK (dilution at 1:200,
ab166624, Abcam) was performed. The sections were evaluated by
light microscopic examination, and cellular localization of the protein
and immunostaining level in each section were assessed by two
pathologists. The staining patterns were scored as follows: negative,
weak (less than 30% of cells with positive staining), moderate (less than
60% but more than 30% of cells with positive staining), and strong
positive (more than 60% of cells with positive staining) according to the
immunostaining intensity. Both negative immunostaining and weak
immunostaining were categorized into the low-expression group;
moderate immunostaining and strong immunostaining were catego-
rized into high expression.
Statistical Analysis
Statistical analysis was carried out using SPSS 17.0 version (SPSS,
Chicago, IL) and Graphpad Prism 5.0. Data were expressed as mean ±
SD and were analyzed by Student's t test and χ2 test as appropriate.
Kaplan-Meier survival curves were plotted, and log rank test was
done. P value b .05 was defined as statistically significant. *P b .05,
**P b .01, and ***P b .001 in comparison with the control group.
Results
Expression of DEK
To detect the DEK expression status in pancreatic cancer tissues as
well as paired normal control tissues, immunohistochemistry was
carried out with pancreatic cancer tissue microarray that consisted ofFigure 1.DEKwas significantly upregulated in pancreatic cancer in co
in pancreatic cancer tissues and normal pancreatic tissue with tissuem
with different expression status of DEK, ranging from low expression a
pancreatic tissue, were taken at different magnifications in pancreatic81 cases of pancreatic cancer tissues and 79 cases of paired normal
control tissues. It can be seen that DEK was mainly immunohisto-
chemically sublocated in nucleus in cells and that DEK was
significantly upregulated in pancreatic cancer tissues as compared
with paired normal control tissues (P = .000) (Figure 1). Actually,
DEK was heterogeneously expressed in pancreatic cancer tissues, with
its expression being weakly, moderately, and strongly positive.
However, DEK expression was comparatively homogeneously in paired
normal control tissues, with its expression being negative or weak.
Clinicopathologically, with the exception of pancreatic cancer tissues
and paired normal control tissues, there was also statistically significant
difference of DEK expression between T classification (P = .033),
clinical stage (P = .023), lymph node metastases (P = .001),
differentiation degree (P = .009), and M classification (P = .012)
(Table 1). However, there was no significant association between DEK
expression and demographic parameters, such as gender and age.
Clinicopathological significance analysis of DEK
To observe whether or not there was correlation between DEK
expression and overall prognosis, Kaplan-Meier survival analysis was
carried out. Of 81 cases of pancreatic cancer tissues, 46 cases was
classified as having high DEK expression, and the rest (35 cases) had
low expression of DEK according to our histopathological evaluation
criteria. It was found that there was extremely significant difference of
overall prognosis between patients with high DEK expression and
with low DEK expression (Figure 2), suggesting that DEK expression
could be used as a prognostic marker for patients diagnosed with
pancreatic cancer.Identification of miR-200a downstream target
Having found that DEK was significantly overexpressed in
pancreatic cancer tissues, we sought to find out its own upstream
regulator from the angle of micoRNA. Using bioinformatics, we
predicted that miR-200a was an upstream regulatory miRNA of DEKmparison with paired normal control tissue. Immunostaining of DEK
icroarray by DEK antibody (1:200). Three representative photographs
nd high expression in pancreatic cancer tissues as well as in normal
cancer tissues and normal pancreatic tissue, respectively.
Table 1. The Clinicopathological Significance of DEK Expression in Pancreatic Cancer Tissues
Clinicopathological
Parameters
Total DEK Expression χ2 P
Value
High (++, +++) Low (−, +)
Pancreatic cancer 81 46 35 32.044 .000
Normal control 79 11 68
Gender
Male 41 26 15 1.485 .266
Female 40 20 20
Age
≤60 36 19 17 0.425 .652
N60 45 27 18
T classification
T1-2 28 11 17 5.343 .033
T3-4 53 35 18
Clinical stage
Stage I-II 32 13 19 5.633 .023
Stage III-IV 49 33 16
Lymph node metastases
No 38 14 24 12.662 .001
N1-2 43 32 11
Differentiation degree
Well-moderate 31 10 21 7.491 .009
Low 50 36 14
M classification
M0 33 13 20 6.868 .012
M1-2 48 33 15
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assay was performed to analyze the actual regulation and control
between miR-200a and DEK gene. It was found that miR-200a can
directly regulate and control the transcriptional activity of DEK genes
(Figure 3E). Based on this, we’ve simultaneously detected the basalFigure 2. High expression of DEK was significantly associated
with poor prognosis. Kaplan-Meier survival analysis of overall prognosis
was performed between patients with high DEK expression (35 cases)
and patients with low DEK (46 cases). In terms of immunostaining
intensity, both negative (−) immunostaining and weak (+) immuno-
staining were categorized into the low-expression group, whereas
medium (++) immunostaining and strong (+++) immunostaining
were categorized into the high-expression group. Log-rank test was
used to statistically analyze the difference.expression status of miR-200a in clinical pancreatic cancer samples
(Figure 3A), and both miR-200a (Figure 3B) and DEK (Figure 3C)
gene were also assayed in vitro in pancreatic cancer cell lines. It can be
seen that there was a tendency that miR-200a negatively correlated
with DEK. To further confirm, we’ve chosen two different kinds of
pancreatic cancer cell lines with contrast expression status of
miR-200a or DEK. Using transfection with miR-200a mimics or
miR-200a inhibitor, it was shown that there was negative regulation
between miR-200a and DEK expression (Figure 3F).
Functional analysis of miR-200a
To investigate the biological role of miR-200a in pancreatic cancer
cells, we’ve firstly chosen two different kinds of pancreatic cancer cell
lines with contrast expression status of miR-200a or DEK. Then,
we’ve used both knockdown and reexpression strategy on cell lines in
vitro to explore the possible role of miR-200a in terms of
proliferation, migration, and invasion. MTT assay showed that
reexpression of miR-200a could markedly suppress the proliferation
of pancreatic cancer cell lines (Figure 4A). In addition, wound-healing
assay showed that reexpression of miR-200a could significantly
suppress the migration (Figure 4B); Transwell assay showed that
reexpression of miR-200a could also remarkably inhibit the invasive
ability (Figure 4C), suggesting that miR-200a plays an antitumor role
in pancreatic cancer cells.Discussion
In our study, we have for the first time identified that DEK gene was a
direct downstream target gene of miR-200a in PDAC, finding that
miR-200a was significantly overexpressed in PDAC tissues compared
with paired normal control. Overexpression of miR-200a can
decrease the level of DEK, suppressing the proliferation, migration,
and invasion of PDAC cells. Our study suggests that miR-200a may
be used as a novel potential marker in prediction of metastasis
of PDAC.
PDAC is the fourth most common cause of death from cancer. Its
5-year survival rate is less than 5%. This poor prognosis is mostly due
to the cancer's early invasion and metastasis formation, leading to an
initial diagnosis at an advanced incurable stage in the majority of
patients [10]. The molecular mechanisms underlying the invasion
and metastasis of PDAC remain to be clarified. Epithelial to
mesenchymal transition (EMT) is a developmental process that
leads the phenotype shift from an epithelial morphology to a motile,
fibroblast-like morphology [11]. Recent studies showed that EMT is
involved in the invasion and metastasis of many types of carcinomas
including PDAC [2,12,13]. In the regulation of EMT in PDAC,
miR-200a has been found to be able to suppress the process by which
PDAC cells metastasized further [2]. Based on the discovery, we’ve
therefore hypothesized that miR-200a could play an important role in
suppressing the metastasis of PDAC cells. To test the hypothesis,
we’ve analyzed the role of miR-200a on PDAC cell lines ex vivo. It
was found that reexpression of miR-200a using transfection with
miR-200a mimics was able to suppress the proliferation, migration,
and invasion of PDAC cell lines. Meanwhile, the phenotype was
rescued by knocking down of miR-200a with transfection of miR-200a
inhibitor, suggesting that miR-200a can suppress the proliferation,
migration, and invasion of PDAC cells.
It has been well known that miRNAs regulated gene expression at
the posttranscriptional level through both translational inhibition and
Figure 3. MiR-200a directly and negatively regulated DEK gene. (A) miR-200a was significantly upregulated in normal pancreatic tissues
compared with pancreatic tissues. miR-200a was detected using qRT-PCR in 81 cases of fresh pancreatic cancer tissues and its paired
normal control tissues. (B) Basal level of miR-200a was detected using qRT-PCR technique in four different pancreatic cancer cell lines
(PK-1, KLM-1, PK-8, and AsPC-1). (C) Endogenous expression level of DEK gene was detected using Western blot in four different
pancreatic cancer cell lines (PK-1, KLM-1, PK-8, and AsPC-1). (D) DEK gene was bioinformatically predicted as target of miR-200a using
online software (http://www.microrna.org/). (E) Luciferase reporter assay was performed to confirm that DEK gene was a direct and
downstream target of miR-200a. (F) Western blot was carried out finding that miR-200a negatively regulated DEK gene.
Independent-sample t test was carried out to analyze the statistical difference. *P b .05, **P b .01, and ***P b .001 compared with
control group.
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luciferase reporter assay, we’ve identified that DEK gene was a direct,
downstream target of miR-200a, which has never been reported ever
before. DEK gene has been found to be significantly overexpressed in
various cancers [7,15–17], but it has been never reported regarding its
possible role in PDAC with the exception of one previous study that
found and mentioned a potential liver metastasis gene [9], but there
has been no follow-up study of DEK’s biological function in PDAC.
In our study, we firstly identified the role of DEK gene in PDAC cells
as oncoprotein that promotes the proliferation, migration, and
invasion of PDAC cells, which is totally in line with and in agreement
with the previous definition of DEK in various cancers [16,18–20].
In our study, we’ve just only employed the PDAC cell lines to
identify that the DEK gene was a direct and down-stream target of
miR-200a; it makes sense that we should have confirmed the
association between miR-200a expression status and DEK expression
level on clinical tissues with PDAC, but given that the PDAC clinical
tissues are unavailable at hand, we’ve failed to confirm the
relationship between miR-200a and DEK on the tissue level, which
is one limitation of our study. Another limitation is that, in
consideration that miR-200 family, consisted of miR-200a,miR-200b, and miR-200c, have been reported to play a key role
in the regulation (to be exact, suppression) of EMT process,
indicating that miR-200b and miR-200c might have the same role
as miR-200a did in the suppression of migration and invasion of
PDAC cells. We should have meanwhile analyzed the possible role of
miR-200b and miR-200c, respectively, in PDAC tissues. Thus, in the
following, we are going to overcome the attendant limitations of the
present study.
Together, our study demonstrated that miR-200a suppresses the
metastasis in pancreatic PDAC through downregulation of DEK,
suggesting that miR-200a may be used as a novel potential marker in
prediction of metastasis of PDAC.
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Figure 4.MiR-200a can significantly suppress the proliferation, migration, and invasion of pancreatic cancer cell lines. (A) MTT assay was
performed to analyze the proliferative variation after transfection with miR-200a mimics into AsPC-1 cells where basal level of miR-200a
was lowest among the four different kinds of pancreatic cancer cell lines and transfection with miR-200a-inhibitor into PK-1 cells where
basal level of miR-200a was highest among the four different kinds of pancreatic cancer cell lines. The absorbance value was detected at
24, 48, 72, and 96 hours posttransfection. (B) Wound-healing assay was qualitatively and quantitatively carried out to detect the migratory
variation in PK-1 and AsPC-1 cells after transfection with miR-200a inhibitor and miR-200a mimics, respectively. (C) Transwell assay was
conducted to analyze the invasive variation in PK-1 and AsPC-1 cells after transfection with miR-200a inhibitor and miR-200a mimics,
respectively. Independent-sample t test was employed. *P b .05 and **P b .01 in comparison with control group.
30 MiR-200a in Pancreatic Ductal Adenocarcinoma Wu et al. Translational Oncology Vol. 9, No. 1, 2016References
[1] Sclafani F, Iyer R, Cunningham D, and Starling N (2015). Management of
metastatic pancreatic cancer: current treatment options and potential new
therapeutic targets. Crit Rev Oncol Hematol 95(3), 318–336.
[2] Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S, Wang Y, Guo Q,Wang L, and Huang Y,
et al (2014). MiR-200a inhibits epithelial-mesenchymal transition of pancreatic
cancer stem cell. BMC Cancer 14, 85.
[3] ShenA, LinW,ChenY, Liu L,ChenH,ZhuangQ,Lin J, SferraTJ, andPeng J (2015).
PienTzeHuang inhibitsmetastasis of humancolorectal carcinoma cells viamodulationof
TGF-beta1/ZEB/miR-200 signaling network. Int J Oncol 46(2), 685–690.
[4] Soubani O, Ali AS, Logna F, Ali S, Philip PA, and Sarkar FH (2012).
Re-expression of miR-200 by novel approaches regulates the expression of PTEN
and MT1-MMP in pancreatic cancer. Carcinogenesis 33(8), 1563–1571.
[5] Feng J, Wang J, Chen M, Chen G, Wu Z, Ying L, Zhuo Q, Zhang J, and Wang
W (2015). miR-200a suppresses cell growth and migration by targeting MACC1
and predicts prognosis in hepatocellular carcinoma. Oncol Rep 33(2), 713–720.
[6] Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, and Lin Z (2013). DEK over
expression as an independent biomarker for poor prognosis in colorectal cancer.
BMC Cancer 13, 366.[7] Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A,
Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, and Perez N,
et al (2014). DEK is a potential marker for aggressive phenotype and irinotecan-based
therapy response in metastatic colorectal cancer. BMC Cancer 14, 965.
[8] Lin L, Piao J, Ma Y, Jin T, Quan C, Kong J, Li Y, and Lin Z (2014). Mechanisms
underlying cancer growth and apoptosis by DEK overexpression in colorectal
cancer. PLoS One 9(10), e111260.
[9] Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K,
Ishikawa O, Ohgaki K, Kashimura N, and Miyamoto M, et al (2004).
Genome-wide cDNAmicroarray analysis of gene expression profiles in pancreatic
cancers using populations of tumor cells and normal ductal epithelial cells
selected for purity by laser microdissection. Oncogene 23(13), 2385–2400.
[10] Honselmann KC, Pross M, Jung CM, Wellner UF, Deichmann S, Keck T, and
Bausch D (2015). Regulation mechanisms of the hedgehog pathway in pancreatic
cancer: a review. JOP 16(1), 25–32.
[11] Cano CE, Motoo Y, and Iovanna JL (2010). Epithelial-to-mesenchymal transition
in pancreatic adenocarcinoma. TheScientificWorldJOURNAL 10, 1947–1957.
[12] Satoh K, Hamada S, and Shimosegawa T (2015). Involvement of epithelial
to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
J Gastroenterol 50(2), 140–146.
Translational Oncology Vol. 9, No. 1, 2016 MiR-200a in Pancreatic Ductal Adenocarcinoma Wu et al. 31[13] Wu Q, Miele L, Sarkar FH, and Wang Z (2012). The role of EMT in pancreatic
cancer progression. Pancreat Disord Ther 2(3).
[14] Fabian MR, Sundermeier TR, and Sonenberg N (2010). Understanding how
miRNAs post-transcriptionally regulate gene expression. Prog Mol Subcell Biol 50,
1–20.
[15] Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH,
and Haegert A, et al (2015). Identification of DEK as a potential therapeutic
target for neuroendocrine prostate cancer. Oncotarget 6(3), 1806–1820.
[16] Wang X, Lin L, Ren X, Lin Z, Li Z, Li C, and Jin T (2014). High expression of
oncoprotein DEK predicts poor prognosis of small cell lung cancer. Int J Clin Exp
Pathol 7(8), 5016–5023.[17] Liu S, Wang X, Sun F, Kong J, Li Z, and Lin Z (2012). DEK overexpression is
correlated with the clinical features of breast cancer. Pathol Int 62(3), 176–181.
[18] Sanden C, Jarvstrat L, Lennartsson A, Brattas PL, Nilsson B, and Gullberg U
(2014). The DEK oncoprotein binds to highly and ubiquitously expressed genes
with a dual role in their transcriptional regulation. Mol Cancer 13, 215.
[19] Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, and Trama JP
(2011). Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.
BMC Cancer 11, 234.
[20] Sanden C, Nilsson HJ, and Gullberg U (2015). The DEK oncoprotein is
upregulated by multiple leukemia-associated fusion genes. Blood Cells Mol Dis
54(3), 284–285.
